{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:49:42Z","timestamp":1768553382276,"version":"3.49.0"},"posted":{"date-parts":[[2021,9,20]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":21,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,9,22]]},"abstract":"<jats:title>Summary<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It\u2019s being developed in Thailand, Vietnam, and Brazil; herein are initial results from Thailand.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1\/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy adults aged 18-59 years, non-pregnant and negative for SARS-CoV-2 antibodies were eligible. Participants were block randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 \u00b5g\u00b1CpG1018 (a toll-like receptor 9 agonist), 3 \u00b5g\u00b1CpG1018, 10 \u00b5g, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol.\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04764422\">NCT04764422<\/jats:ext-link>\n                    ).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enrolled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (&lt;63%), fatigue (&lt;35%), headache (&lt;32%), and myalgia (&lt;32%). The proportion reporting a vaccine-related AE ranged from 5\u00b77% to 17\u00b71% among vaccine groups and was 2\u00b79% in controls; there was no vaccine-related serious adverse event. The 10 \u00b5g formulation\u2019s immunogenicity ranked best, followed by 3 \u00b5g+CpG1018, 3 \u00b5g, 1 \u00b5g+CpG1018, and 1 \u00b5g formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 122\u00b723 IU\/mL (1 \u00b5g, 95% CI 86\u00b740-172\u00b791) to 474\u00b735 IU\/mL (10 \u00b5g, 95% CI 320\u00b790-701\u00b719), with 93\u00b79% to 100% of vaccine groups attaining a \u22654-fold increase over baseline.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 \u00b5g and 3 \u00b5g+CpG1018 formulations advanced to phase 2.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Funding<\/jats:title>\n                  <jats:p>National Vaccine Institute (Thailand), National Research Council (Thailand), Bill &amp; Melinda Gates Foundation, National Institutes of Health (USA)<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2021.09.17.21263758","type":"posted-content","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T04:00:37Z","timestamp":1632196837000},"source":"Crossref","is-referenced-by-count":3,"title":["Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1\/2 Trial"],"prefix":"10.64898","author":[{"given":"Punnee","family":"Pitisuttithum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viravarn","family":"Luvira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saranath","family":"Lawpoolsri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sant","family":"Muangnoicharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supitcha","family":"Kamolratanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaisith","family":"Sivakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piengthong","family":"Narakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somchaiya","family":"Surichan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumalee","family":"Prangpratanporn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suttida","family":"Puksuriwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Lamola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laina D","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Raghunandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weerapong","family":"Phumratanaprapin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Amanat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Lin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruangchai","family":"Kaweepornpoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarwat","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjari","family":"Lal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"McCroskery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Mena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Meseck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjaluck","family":"Phonrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yupa","family":"Sabmee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratsamikorn","family":"Singchareon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Slamanig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nava","family":"Suthepakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnstone","family":"Tcheou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narumon","family":"Thantamnu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sompone","family":"Theerasurakarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanakrit","family":"Vilasmongkolchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Garcia-Sastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kittisak","family":"Poopipatpol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponthip","family":"Wirachwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hjorth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce L","family":"Innis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2021092412550740000_2021.09.17.21263758v2.1","unstructured":"(WHO) WHO. https:\/\/www.who.int\/director-general\/speeches\/detail\/director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-9-april-2021. 2021."},{"issue":"3","key":"2021092412550740000_2021.09.17.21263758v2.2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.vaccine.2020.12.018","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2019","volume":"39","year":"2021","journal-title":"Vaccine"},{"key":"2021092412550740000_2021.09.17.21263758v2.3","doi-asserted-by":"crossref","unstructured":"Sun W , McCroskery S , Liu WC , et al. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel) 2020; 8(4).","DOI":"10.3390\/vaccines8040771"},{"key":"2021092412550740000_2021.09.17.21263758v2.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0826"},{"key":"2021092412550740000_2021.09.17.21263758v2.5","doi-asserted-by":"crossref","unstructured":"Sun W , Liu Y , Amanat F , et al. A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters. bioRxiv 2021: 2021.07.06.451301.","DOI":"10.1101\/2021.07.06.451301"},{"key":"2021092412550740000_2021.09.17.21263758v2.6","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6445-1_2"},{"key":"2021092412550740000_2021.09.17.21263758v2.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030237"},{"key":"2021092412550740000_2021.09.17.21263758v2.8","doi-asserted-by":"crossref","unstructured":"Hsieh CL , Goldsmith JA , Schaub JM , et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 2020.","DOI":"10.1101\/2020.05.30.125484"},{"issue":"10282","key":"2021092412550740000_2021.09.17.21263758v2.9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO International Standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2021092412550740000_2021.09.17.21263758v2.10","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2. neutralising antibody by wild-type plaque reduction neutralisation, microneutralisation and pseudotyped virus neutralisation assays","volume":"16","year":"2021","journal-title":"Nat Protoc"},{"key":"2021092412550740000_2021.09.17.21263758v2.11","doi-asserted-by":"crossref","unstructured":"Havranek KE , Jimenez AR , Acciani MD , et al. SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. Viruses 2020; 12(12).","DOI":"10.3390\/v12121465"},{"issue":"7854","key":"2021092412550740000_2021.09.17.21263758v2.12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","year":"2021","journal-title":"Nature"},{"key":"2021092412550740000_2021.09.17.21263758v2.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh2644"},{"key":"2021092412550740000_2021.09.17.21263758v2.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.006"},{"key":"2021092412550740000_2021.09.17.21263758v2.15","unstructured":"Carre\u00f1o JM , Alshammary H , Singh G , et al. Reduced. neutralising activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37. medRxiv 2021: 2021.07.21.21260961."},{"issue":"4","key":"2021092412550740000_2021.09.17.21263758v2.16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chom.2021.03.009","article-title":"Infection- and vaccine-induced antibody binding and neutralisation of the B.1.351 SARS-CoV-2 variant","volume":"29","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"24","key":"2021092412550740000_2021.09.17.21263758v2.17","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc2103740","article-title":"Neutralisation of SARS-CoV-2 Variants B.1.429 and B.1.351","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"2021092412550740000_2021.09.17.21263758v2.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2798-3"},{"key":"2021092412550740000_2021.09.17.21263758v2.19","doi-asserted-by":"crossref","unstructured":"Earle KA , Ambrosino DM , Fiore-Gartland A , et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021.","DOI":"10.1101\/2021.03.17.20200246"},{"key":"2021092412550740000_2021.09.17.21263758v2.20","doi-asserted-by":"crossref","unstructured":"Khoury DS , Cromer D , Reynaldi A , et al. neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021.","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2021092412550740000_2021.09.17.21263758v2.21","unstructured":"Gilbert PB , Montefiori DC , McDermott A , et al. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv 2021: 2021.08.09.21261290."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.09.17.21263758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:25:09Z","timestamp":1768487109000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.09.17.21263758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1101\/2021.09.17.21263758","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.eclinm.2022.101323","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2021,9,20]]},"subtype":"preprint"}}